骨肉瘤相关的lncRNA研究进展

白广建; 韩智涛; 刘戈; 陈广辉; 信保全; 刘铁龙

doi:10.3969/j.issn.1000-8179.2018.06.949

骨肉瘤相关的lncRNA研究进展

doi: 10.3969/j.issn.1000-8179.2018.06.949

白广建^{①, ②,},
韩智涛^②,
刘戈^{①, ②},
陈广辉^②,
信保全^{①, ②},
刘铁龙^②, ,

①.
泰山医学院（山东省泰安市271000）
②.
上海长征医院脊柱肿瘤中心

基金项目:

国家自然科学基金项目 81372874

详细信息

作者简介:
白广建专业方向为脊柱外科及骨肿瘤治疗。E-mail：czyybai_tsmc@163.com

通讯作者:
刘铁龙 czyyltl@163.com

计量
- 文章访问数: 108
- HTML全文浏览量: 16
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2017-11-06
- 修回日期: 2018-03-07
- 刊出日期: 2018-03-30

Research progress on lncRNA related to osteosarcoma

Bai Guangjian^{①, ②
,},
Han Zhitao^②,
Liu Ge^{①, ②},
Chen Guanghui^②,
Xin Baoquan^{①, ②},
Liu Tielong^{②
, ,}

①.
Taishan Medical University, Taian 271000, China
②.
The Spinal Tumor Center, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

Funds:

National Natural Science Foundation of China 81372874

More Information

Corresponding author: Tielong Liu; czyyltl@163.com

摘要

摘要: 骨肉瘤是临床常见的原发性恶性骨肿瘤，由于恶性程度高，转移发生早，骨肉瘤的治疗效果至今仍不理想，研究骨肉瘤恶性生物学特征的分子机制并探索高效的治疗方式，已成为国内外对骨肉瘤研究的热点。lncRNA（long non-coding RNA）是一类长链非编码RNA，参与多种细胞功能的调控，对肿瘤的发生发展起重要作用。近年来，lncRNA在骨肉瘤中的研究报道越来越多，lncRNA通过与蛋白质、mRNA、miRNA等相互作用，影响骨肉瘤细胞的增殖、侵袭和迁移。本文结合近年报道，对lncRNA在骨肉瘤分子机制中的研究做一综述。
- 骨肉瘤 /
- lncRNA /
- 分子机制 /
- 研究进展
Abstract: Osteosarcoma is a clinically common primary malignant bone tumor. Its treatment is still not ideal because of the high degree of malignancy and early metastasis. Understanding the molecular mechanism and the biological characteristics of malignant osteosarcoma, and exploring the effective treatment have become the focus of osteosarcoma research at home and abroad. A long noncoding RNA, lncRNA, is involved in the regulation of a variety of cellular functions and plays an important role in the development of osteosarcoma. Recently, lncRNA has been increasingly reported in osteosarcoma research. It has been found to affect the proliferation, invasion, and migration of osteosarcoma cells by interacting with proteins, mRNAs, and miRNAs. This article reviews the research on lncRNA based on recent reports regarding its role in the molecular mechanism of osteosarcoma.
- osteosarcoma /
- lncRNA /
- molecular mechanisms /
- research progress

HTML全文

参考文献(48)

[1]	Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies[J]. Clin Adv Hematol, 2010, 8(10):705-718.
[2]	Hua Z, Chen Z, Wang X, et al. Long non-coding RNA: a new player in cancer[J]. J Hemat Oncol, 2013, 6(1):37. doi: 10.1186/1756-8722-6-37
[3]	Broadhead ML, Clark JC, Myers DE, et al. The molecular pathogenesis of osteosarcoma: a review[J]. Sarcoma, 2011, 2011:959248.
[4]	Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program[J]. Cancer, 2009, 115(7):1531-1543. doi: 10.1002/cncr.v115:7
[5]	Cotterill SJ, Wright CM, Pearce MS, et al. Stature of young people with malignant bone tumors[J]. Pediatric Blood Cancer, 2004, 42(1):59-63. doi: 10.1002/(ISSN)1545-5017
[6]	赵晓蕾, 蔡林, 邓洲铭. microRNA与骨肉瘤的研究进展[J].中国骨与关节杂志, 2014, 3(10):773-778. doi: 10.3969/j.issn.2095-252X.2014.10.012
[7]	Wesolowski R, Budd GT. Use of chemotherapy for patients with bone and soft-tissue sarcomas[J]. Cleve Clin J Med, 2010, 77(Suppl 1):23-26. https://cwru.pure.elsevier.com/en/publications/use-of-chemotherapy-for-patients-with-bone-and-soft-tissue-sarcom-2
[8]	Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma[J]. Cancer, 2009, 115(22):5339-5348. doi: 10.1002/cncr.24566
[9]	Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs[J]. Nature, 2012, 482(7385):339-346. doi: 10.1038/nature10887
[10]	Cheetham SW, Gruhl F, Mattick JS, et al. Long noncoding RNAs and the genetics of cancer[J]. Br J Cancer, 2013, 108(12):2419-2425. doi: 10.1038/bjc.2013.233
[11]	Gibb EA, Brown CJ, Wan LL. The functional role of long non-coding RNA in human carcinomas[J]. Mole Cancer, 2011, 10(1):38. doi: 10.1186/1476-4598-10-38
[12]	Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions[J]. Nat Rev Gene, 2009, 10(3):155-159. doi: 10.1038/nrg2521
[13]	Li JP, Liu LH, Li J, et al. Microarray expression profile of long noncoding RNAs in human osteosarcoma[J]. Biochem Bio Res Commun, 2013, 433 (2):200. doi: 10.1016/j.bbrc.2013.02.083
[14]	Zhu KP, Zhang CL, Shen GQ, et al. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.[J]. Int J Clin Exp Path, 2015, 8(8):8754. http://www.ijcep.com/files/ijcep0011039.pdf
[15]	Yin Z, Ding H, He E, et al. Overexpression of long non-coding RNA MFI2 promotes cell proliferation and suppresses apoptosis in human osteosarcoma[J]. Onco Rep, 2016, 36(4):2033-2040. doi: 10.3892/or.2016.5013
[16]	Sun J, Wang X, Fu C, et al. Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3[J]. Mole Biol Rep, 2016, 43(5):427-436. doi: 10.1007/s11033-016-3975-1
[17]	Liu SH, Zhu JW, Xu HH, et al. A novel antisense long non-coding RNA SATB2-AS1 overexpresses in osteosarcoma and increases cell proliferation and growth[J]. Mole Cell Bio, 2017, 430(1-2):1-10. doi: 10.1007/s11010-017-2953-9
[18]	Zhao H, Hou W, Tao J, et al. Upregulation of lncRNA HNF1A-AS1 promotes cell proliferation and metastasis in osteosarcoma through activation of the Wnt/β-catenin signaling pathway[J]. Am J Trans Res, 2016, 8(8):3503.
[19]	Hua Z, Jing M. Role of long noncoding RNA HOTAIR in the growth and apoptosis of osteosarcoma cell MG-63[J]. Biomed Res Int, 2016, 2016 (6):5757641.
[20]	Wang Y, Liang T, Wang Y, et al. Long non-coding RNA AK093407 promotes proliferation and inhibits apoptosis of human osteosarcoma cells via STAT3 activation[J]. Am J Cancer Res, 2017, 7(4):892-902. http://www.ajcr.us/files/ajcr0051762.pdf
[21]	Wang H, Yu Y, Fan S, et al. Knockdown of long noncoding RNA TUG1 inhibits the proliferation and cellular invasion of osteosarcoma cells by sponging miR-153[J]. Oncol Res, 2017, 42(12):505.
[22]	Lv GY, Yu Y, Fan S, et al. Knockdown of Long Noncoding RNA TUG1 Inhibits the Proliferation and Cellular Invasion of Osteosarcoma Cells By Sponging MiR-153[J]. Oncol Res, 2017, 4(12):721.
[23]	Han F, Wang C, Wang Y, et al. Long noncoding RNA ATB promotes osteosarcoma cell proliferation, migration and invasion by suppressing miR-200s[J]. Am J Cancer Res, 2017, 7(4):770. http://www.ajcr.us/files/ajcr0046063.pdf
[24]	Cong M, Li J, Jing R, et al. Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma[J]. Tumor Biol, 2016, 37(7):9441-9450. doi: 10.1007/s13277-015-4414-y
[25]	Peng ZQ, Lu RB, Xiao DM, et al. Increased expression of the lncRNA BANCR and its prognostic significance in human osteosarcoma[J]. Gene Mole Res, 2016, 15(1):28.
[26]	Bo W, Yun S, Yang Q, et al. Overexpression of long non-coding RNA HOTAIR promotes tumor growth and metastasis in human osteosarcoma[J]. Mole Cells, 2015, 38(5):432-440. doi: 10.14348/molcells.2015.2327
[27]	Ruan W, Pei W, Feng S, et al. Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin gene expression in human osteosarcoma cells [J]. Tumour Biol, 2016, 37(3):4065-4073. doi: 10.1007/s13277-015-4256-7
[28]	Huo Y, Li Q, Wang X, et al. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2[J]. Oncotarget, 2017, 8(29):46993-47006.
[29]	Li W, Xie P, Wen HR. Overexpression of lncRNA UCA1 promotes osteosarcoma progression and correlates with poor prognosis[J]. J Bone Oncol, 2016, 5(2):80-85. doi: 10.1016/j.jbo.2016.05.003
[30]	Chen F, Mo J, Zhang L. Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription[J]. Tumour Biol J Int Soci Oncodevelop Biol Medi, 2016, 37 (10):1-10. doi: 10.1007/s13277-016-5256-y
[31]	Yang W, Liu X, Choy E, et al. Targeting hedgehog‐GLI‐2 pathway in osteosarcoma[J]. J Orthop Res Offi Pub Orthopa Res Soci, 2013, 31(3): 502-509. doi: 10.1002/jor.v31.3
[32]	Thiyagarajan S, Bhatia N, Reaganshaw S, et al. Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells[J]. Cancer Res, 2007, 67(22):10642-10646. doi: 10.1158/0008-5472.CAN-07-2015
[33]	Nagao H, Ijiri K, Hirotsu M, et al. Role of GLI2 in the growth of human osteosarcoma[J]. J Path, 2011, 224(2):169-179. doi: 10.1002/path.2880
[34]	Preker P, Almvig K, Christensen MS, et al. PROMoter uPstream transcripts share characteristics with mRNAs and are produced upstream of all three major types of mammalian promoters[J]. Nucl Acids Res, 2011, 39(16):7179-7193. doi: 10.1093/nar/gkr370
[35]	Taft RJ, Kaplan CD, Simons C, et al. Evolution, biogenesis and function of promoter-associated RNAs[J]. Cell Cycle, 2009, 8(15):2332-2338. doi: 10.4161/cc.8.15.9154
[36]	Preker P, Nielsen J, Kammler S, et al. RNA Exosome depletion reveals transcription upstream of active human promoters[J]. Sci, 2008, 322 (5909):1851-1854. doi: 10.1126/science.1164096
[37]	Jacquier A. The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs[J]. Nat Rev Gene, 2009, 10 (12):833. doi: 10.1038/nrg2683
[38]	Acker T, Diez-Juan A, Aragones J, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha[J]. Cancer Cell, 2005, 8(2):131-141. doi: 10.1016/j.ccr.2005.07.003
[39]	Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells[J]. Cancer Cell, 2009, 15(6):501-513. doi: 10.1016/j.ccr.2009.03.018
[40]	Wang Y, Yao J, Meng H, et al. A novel long non-coding RNA, hypoxiainducible factor-2 promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro[J]. Mole Med Rep, 2015, 11 (4):2534-2540. doi: 10.3892/mmr.2014.3024
[41]	Li W, He X, Xue R, et al. Combined over-expression of the hypoxiainducible factor 2 gene and its long non-coding RNA predicts unfavorable prognosis of patients with osteosarcoma[J]. Path Res Prac, 2016, 212(10):861-866. doi: 10.1016/j.prp.2016.06.013
[42]	Tian ZZ, Guo XJ, Zhao YM, et al. Decreased expression of long noncoding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma[J]. Int J Clin Exp Pathol, 2014, 8(11):15138-15142. doi: 10.1080/15384047.2017.1394543
[43]	Qi P, Xu MD, Ni SJ, et al. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer[J]. J Trans Med, 2013, 11(1): 122. doi: 10.1186/1479-5876-11-122
[44]	Zhang CL, Zhu KP, Shen GQ, et al. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma[J]. Tumor Biol, 2016, 37(2): 2737-2748. doi: 10.1007/s13277-015-4130-7
[45]	Wang Y, Zhang L, Zheng X, et al. Long non-coding RNA LINC00161 sensitizes osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis[J]. Cancer Letters, 2016, 382(2):137-146. doi: 10.1016/j.canlet.2016.08.024
[46]	Zhang CL, Zhu KP, Ma XL. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2[J]. Cancer Lett, 2017, 396:66-75. doi: 10.1016/j.canlet.2017.03.018
[47]	Wang Z, Liu Z, Song W. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy[J]. Oncotarget, 2017, 8(19):31465. https://www.sigmaaldrich.com/catalog/papers/28415557
[48]	Ma B, Li M, Zhang L, et al. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma[J]. Tumour Biol, 2015, 37(4):1-11. doi: 10.1007/s13277-015-4301-6